Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment.

Autor: Mulder TA; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Andersson ML; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden., Peña-Pérez L; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden., Heimersson K; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Xagoraris I; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden., Wahlin BE; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Månsson R; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden., Hansson L; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden., Rassidakis G; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Palma M; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Jazyk: angličtina
Zdroj: HemaSphere [Hemasphere] 2022 Oct 26; Vol. 6 (11), pp. e794. Date of Electronic Publication: 2022 Oct 26 (Print Publication: 2022).
DOI: 10.1097/HS9.0000000000000794
Abstrakt: In classical Hodgkin lymphoma (cHL), the malignant cells represent only a small fraction of the tumor. Yet, they orchestrate a lymphocyte-dominated tumor microenvironment (TME) that supports their survival and growth. The systemic effects of this local immunomodulation are not fully elucidated. Here, we aimed at characterizing circulating lymphocytes and plasma proteins in relation to clinical parameters and treatment effect. Peripheral blood (PB) samples were obtained from 48 consecutive patients at diagnosis and at 2 time points after successful primary treatment. Single-cell suspensions were prepared from lymph node (LN) biopsies obtained for routine diagnostic purposes. Twenty healthy individuals were included as controls. Cells from PB and LN were analyzed by flow cytometry, and plasma proteins by Proximity Extension Assay. We found that the frequencies of T and B cells positively correlated between the LN and the PB compartments. Compared to controls, cHL patients had higher frequencies of proliferating T cells as well as higher expression of programmed death (PD)-1 and cytotoxic T lymphocyte antigen (CTLA)-4 in circulating T cells, and lower naive T-cell frequencies. Advanced-stage patients had fewer NK cells with a functionally impaired phenotype. Differences in the immune profile were observed in patients with a high tumor burden and with high inflammation, respectively. Most of these deviations disappeared after standard first-line treatment. Patients who received radiotherapy involving the mediastinum had low T-cell counts for a prolonged period. Our findings suggest that the immunomodulation of lymphocytes in the TME of cHL might affect immune biomarkers in the PB.
(Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)
Databáze: MEDLINE
Externí odkaz: